Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 21, 2022; 28(31): 4376-4389
Published online Aug 21, 2022. doi: 10.3748/wjg.v28.i31.4376
Published online Aug 21, 2022. doi: 10.3748/wjg.v28.i31.4376
Figure 6 Decision curve analysis was performed in all hepatocellular carcinoma patients to evaluate the clinical practicality of the nomogram for predicting 3- and 5-year overall survival compared with the Barcelona clinic liver cancer staging system model and tumor, node and metastasis staging system model.
A and B: Decision curve analysis of the nomogram, Barcelona clinic liver cancer staging system model and tumor, node and metastasis staging system model in predicting 3- (A) and 5-year (B) OS. In the decision curve, the threshold probability is represented on the x-axis, and the net benefit is represented on the y-axis. A higher curve indicates a greater net benefit at any given threshold probability. The decision curve showed that the nomogram adds more net benefit than traditional staging system models. BCLC: Barcelona clinic liver cancer; TNM: Tumor, node and metastasis.
- Citation: Deng PZ, Zhao BG, Huang XH, Xu TF, Chen ZJ, Wei QF, Liu XY, Guo YQ, Yuan SG, Liao WJ. Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma. World J Gastroenterol 2022; 28(31): 4376-4389
- URL: https://www.wjgnet.com/1007-9327/full/v28/i31/4376.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i31.4376